Ataxia
VIDEO: Omaveloxolone improves neurologic function in Friedreich’s ataxia patients
In this video David Lynch discusses current treatment options for Friedreich's ataxia patients.
Early hyponatremia after starting thiazide associated with increased mortality risk
Patients who develop early hyponatremia after starting thiazide diuretics have a higher mortality risk than those with normal sodium levels, according to retrospective study data.
US awards $11.4M for therapeutic to treat Fragile X-associated tremor
The U.S. Department of Defense has awarded $11.4 million to a Boston-based biotherapeutics firm to advance its novel oral prodrug of endogenous allopregananolone, LYT-300, to treat Fragile X-associated Tremor Ataxia syndrome.
Skyclarys now available to patients with Friedreich’s ataxia
Reata Pharmaceuticals announced that Skyclarys is now commercially available for patients older than 16 years who have Friedreich’s ataxia, a rare degenerative neuromuscular disorder that manifests at a young age.
FDA approves first oral treatment for Friedreich’s ataxia
The FDA has approved Skyclarys, Reata Pharmaceuticals’ oral, once-daily medication to treat Friedreich’s ataxia in people aged 16 years and older.
FDA will not hold advisory committee meeting to discuss NDA for Friedreich’s ataxia drug
Reata Pharmaceuticals Inc. announced the FDA does not plan to hold an advisory committee meeting to discuss the company’s new drug application for an investigational therapeutic to treat Friedreich’s ataxia.
NFL, NFLPA finalize review of updated concussion protocol in wake of Tagovailoa injury
The National Football League and the NFL Players Association have issued a joint statement finalizing review of the league’s concussion protocol, which now prohibits a player from returning to a game if diagnosed with ataxia.
FDA grants priority review for Friedreich’s ataxia treatment
The FDA has granted priority review to Reata Pharmaceuticals Inc.’s new drug application for omaveloxolone to treat patients with Friedreich’s ataxia.